ATHA Valuation

Athira Pharma Inc

Add to Watchlist

Advanced Chart

0.398

+0.004(1.014%)1D

Overview
Forecast
Valuation
Earnings

ATHA Relative Valuation

ATHA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATHA is overvalued; if below, it's undervalued.

Historical Valuation

Athira Pharma Inc (ATHA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.26. The fair price of Athira Pharma Inc (ATHA) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：0.39

Fair

-0.86

Trailing

Forward

0.00

EV/EBITDA

Athira Pharma Inc. (ATHA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.64. The thresholds are as follows: Strongly Undervalued below -10.16, Undervalued between -10.16 and -5.90, Fairly Valued between 2.61 and -5.90, Overvalued between 2.61 and 6.87, and Strongly Overvalued above 6.87. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.57

EV/EBIT

Athira Pharma Inc. (ATHA) has a current EV/EBIT of 0.57. The 5-year average EV/EBIT is -1.21. The thresholds are as follows: Strongly Undervalued below -8.47, Undervalued between -8.47 and -4.84, Fairly Valued between 2.41 and -4.84, Overvalued between 2.41 and 6.04, and Strongly Overvalued above 6.04. The current Forward EV/EBIT of 0.57 falls within the Historic Trend Line -Fairly Valued range.

0.00

Athira Pharma Inc. (ATHA) has a current PS of 0.00. The 5-year average PS is 49.50. The thresholds are as follows: Strongly Undervalued below -1174.79, Undervalued between -1174.79 and -562.65, Fairly Valued between 661.64 and -562.65, Overvalued between 661.64 and 1273.78, and Strongly Overvalued above 1273.78. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Athira Pharma Inc. (ATHA) has a current P/OCF of 0.00. The 5-year average P/OCF is -4.06. The thresholds are as follows: Strongly Undervalued below -15.10, Undervalued between -15.10 and -9.58, Fairly Valued between 1.47 and -9.58, Overvalued between 1.47 and 6.99, and Strongly Overvalued above 6.99. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Athira Pharma Inc. (ATHA) has a current P/FCF of 0.00. The 5-year average P/FCF is -4.12. The thresholds are as follows: Strongly Undervalued below -15.33, Undervalued between -15.33 and -9.73, Fairly Valued between 1.49 and -9.73, Overvalued between 1.49 and 7.09, and Strongly Overvalued above 7.09. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Athira Pharma Inc (ATHA) has a current Price-to-Book (P/B) ratio of 0.49. Compared to its 3-year average P/B ratio of 0.56 , the current P/B ratio is approximately -12.79% higher. Relative to its 5-year average P/B ratio of 0.93, the current P/B ratio is about -47.39% higher. Athira Pharma Inc (ATHA) has a Forward Free Cash Flow (FCF) yield of approximately -450.41%. Compared to its 3-year average FCF yield of -247.89%, the current FCF yield is approximately 81.70% lower. Relative to its 5-year average FCF yield of -154.55% , the current FCF yield is about 191.43% lower.

0.47

P/B

Median3y

0.56

Median5y

0.93

-449.84

FCF Yield

Median3y

-247.89

Median5y

-154.55

Competitors Valuation Multiple

The average P/S ratio for ATHA's competitors is 2.24, providing a benchmark for relative valuation. Athira Pharma Inc Corp (ATHA) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Adaptimmune Therapeutics PLC

Marker Therapeutics Inc

5.41

-26.35%

16.69M

Performance Decomposition

Market capitalization of ATHA increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ATHA in the past 1 year is driven by Unknown.